We are live on ! Find out more
LXEO icon

Lexeo Therapeutics
LXEO

139 hedge funds and large institutions have $459M invested in Lexeo Therapeutics in 2026 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 58 increasing their positions, 38 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

548% more call options, than puts

Call options by funds: $389K | Put options by funds: $60K

53% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 38

4.7% more ownership

Funds ownership: 104.76% → 109.46% (+4.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less funds holding

Funds holding: 146 → 139 (-7)

22% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 27

40% less capital invested

Capital invested by funds: $759M → $459M (-$300M)

Holders
139
Holders Change
-7
Holders Change %
-4.79%
% of All Funds
1.71%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
21
Increased
58
Reduced
38
Closed
27
Calls
$389K
Puts
$60K
Net Calls
+$329K
Net Calls Change
+$336K

Top Buyers

Rank Fund Capital Flow
1
AAA
Affinity Asset Advisors
New York
+$13.1M
2
O
OrbiMed
New York
+$10.5M
3
PBA
Paradigm Biocapital Advisors
New York
+$10.1M
4
Goldman Sachs
Goldman Sachs
New York
+$8.28M
5
SSC
Spruce Street Capital
New York
+$5.34M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$10.1M
2
SL
Siren LLC
Connecticut
-$7.16M
3
SCM
Silverarc Capital Management
Massachusetts
-$6.13M
4
OCA
Octagon Capital Advisors
New York
-$4.43M
5
Verition Fund Management
Verition Fund Management
Connecticut
-$4.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCM
151
Graham Capital Management
Connecticut
– -$327K -32,898 Closed
WG
152
Winton Group
United Kingdom
– -$267K -26,900 Closed
IC
153
IEQ Capital
California
– -$245K -24,692 Closed
PFCS
154
Pale Fire Capital SE
Czech Republic
– -$221K -22,302 Closed
OAC
155
OMERS Administration Corp
Ontario, Canada
– -$208K -20,900 Closed
SG Americas Securities
156
SG Americas Securities
New York
– -$185K -18,640 Closed
PAP
157
Persistent Asset Partners
Hong Kong
– -$159K -16,025 Closed
A
158
AlphaQuest
New York
– -$116K -11,726 Closed
Bessemer Group
159
Bessemer Group
New Jersey
– -$24K -2,380 Closed
AB
160
Amalgamated Bank
New York
– -$20K -1,982 Closed
ACM
161
Aquatic Capital Management
Illinois
– -$10.8K -1,085 Closed
Daiwa Securities Group
162
Daiwa Securities Group
Japan
– -$2K -243 Closed
FFA
163
Farther Finance Advisors
California
– -$566 -57 Closed
RWM
164
Rialto Wealth Management
New York
– -$527 -53 Closed
CA
165
Clearstead Advisors
Ohio
– -$40 -4 Closed
RIL
166
Rothschild Investment LLC
Illinois
– -$10 -1 Closed
3 4 5 6
7

LXEO Hedge Fund Activity: Q1 2026 in Review

139 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q1 2026, worth a combined $459M — down 40% from $759M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of LXEO and 21 opened new positions — a net loss of 6 holders — while 38 trimmed existing stakes and 58 added.

The largest buyer was Affinity Asset Advisors, adding an estimated $13.1M. The largest seller was Avoro Capital Advisors, cutting an estimated $10.1M.

  • 139 institutional investors held Lexeo Therapeutics (LXEO) as of Q1 2026, down from 146 in Q4 2025.
  • Funds reported $459M of Lexeo Therapeutics stock for Q1 2026, down 40% quarter-over-quarter.
  • 21 funds opened new Lexeo Therapeutics positions in Q1 2026 and 27 closed out, a net change of -6 holders.
  • The largest Lexeo Therapeutics buyer in Q1 2026 was Affinity Asset Advisors, an estimated $13.1M added.
  • The largest Lexeo Therapeutics seller in Q1 2026 was Avoro Capital Advisors, an estimated $10.1M sold.

Based on aggregated 13F filings for Q1 2026.